ZYUS.V ZYUS Life Sciences Corporation

Healthcare Pharmaceuticals TSX Venture Exchange
0.3200 CAD
Close of Nov 7, 2026
0.3000 0.7500
Market cap
CAD 25.6M
P/E
-
P/B
4.41x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ZYUS.V undervalued?

Graham number

The Graham number of ZYUS Life Sciences Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ZYUS Life Sciences Corporation fundamental analysis

No fundamental analysis for ZYUS Life Sciences Corporation yet.

ZYUS Life Sciences Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Li…

Full company profile